Safety and tolerability of GV150526 (a glycine site antagonist at the N- methyl-D-aspartate receptor) in patients with acute stroke

Stroke

Volumn 30, Issue 5, 1999, Pages 986-992

  Dyker, Alexander G ^a   Lees, Kennedy R ^a  

^a WESTERN INFIRMARY   (United Kingdom)

Author keywords

Amino acids; Neuroprotection; Stroke, acute

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; BILIRUBIN; GAMMA GLUTAMYLTRANSFERASE; GAVESTINEL; GLUCOSE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PLACEBO;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISTRIBUTION VOLUME; DOSE CALCULATION; DOSE RESPONSE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; GASTROINTESTINAL DISEASE; HUMAN; HYPERBILIRUBINEMIA; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY CLEARANCE; LIVER TOXICITY; MAJOR CLINICAL STUDY; NEUROPROTECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STROKE; TACHYCARDIA; TREATMENT OUTCOME;

EID: 0032925354     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.30.5.986     Document Type: Article

References (11)

1. Bordi F, Pietra C, Ziviani L, Reggiani A. The glycine antagonist GV150526 protects somatosensory evoked potentials and reduces the infarct area in the MCAo model of focal ischemia in the rat. Exp Neurol. 1997;145:1-10.
2. Di Fabio R, Cugola A, Donati D, Feriani A, Gaviraghi G, Ratti E, Trist D, Reggiani A. Identification and pharmacological characterization of GV150526, a novel glycine antagonist as a potent neuroprotective agent. Drugs Future. 1998;23:61-69.
3. Gaviraghi G, Pietra C, Ratti E, Trist D, Reggiani A. GV150526A: a novel glycine antagonist with neuroprotective activity devoid of side-effects associated to NMDA receptor blockade. Cerebrovasc Dis. 1996;6:41-42. Abstract.
4. Reggiani A, Pietra C, Tarter G, Tessari M, Ratti E, Trist D, Gaviraghi G. Pre and post-ischaemia effect of GV150526A in rat transient MCA occlusion. Cerebrovasc Dis. 1996;6(suppl 2):5. Abstract.
5. Muir KW, Lees KR. Clinical experience with excitatory amino acid antagonist drugs. Stroke. 1995;26:503-513.
6. Olney JW. Neurotoxicity of NMDA receptor antagonists: an overview. Psychopharmacol Bull. 1994;30:533-540.
7. Goldstein LB, Samsa GP. Reliability of the National Institutes of Health Stroke Scale: Extension to non-neurologists in the context of a clinical trial. Stroke. 1997;28:307-310.
8. Mahoney FI, Barthel DW. Functional evaluation: the Barthel Index. Md State Med J. 1965;14:61-65.
9. Weir CJ, Murray GD, Dyker AG, Lees KR. Is hyperglycaemia an independent predictor of poor outcome after acute stroke? Results of a long term follow up study. BMJ. 1997;314:1303-1306.
10. Hoke JF, Dyker AG, McAllister AM, Lees KR. Pharmacokinetics of GV150526A following multiple intravenous doses in acute stroke patients. Cerebrovasc Dis. 1997;7(suppl 4):29. Abstract.
11. GAIN European Study Group. Safety and tolerability of GV150526 in acute stroke (GLYB2002). Cerebrovasc Dis. 1998;8(suppl 4):20. Abstract.